In the latest trading session,, 20.15 million Sonnet BioTherapeutics Holdings Inc (NASDAQ:SONN) shares changed hands as the company’s beta touched 0.91. With the company’s most recent per share price at $2.13 changing hands around $0.92 or 76.03% at last look, the market valuation stands at $6.74M. SONN’s current price is a discount, trading about -370.42% off its 52-week high of $10.02. The share price had its 52-week low at $1.08, which suggests the last value was 49.3% up since then. When we look at Sonnet BioTherapeutics Holdings Inc’s average trading volume, we note the 10-day average is 69570.0 shares, with the 3-month average coming to 44.93K.
Analysts gave the Sonnet BioTherapeutics Holdings Inc (SONN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended SONN as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight.
Sonnet BioTherapeutics Holdings Inc (NASDAQ:SONN) trade information
Instantly SONN is in green as seen in intraday trades today. With action 88.50%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -71.60%, with the 5-day performance at 88.50% in the green. However, in the 30-day time frame, Sonnet BioTherapeutics Holdings Inc (NASDAQ:SONN) is 82.05% up. Looking at the short shares, we see there were 60829.0 shares sold at short interest cover period of 1.57 days.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 85.27%. The 2025 estimates are for Sonnet BioTherapeutics Holdings Inc earnings to increase by 69.52%.
SONN Dividends
Sonnet BioTherapeutics Holdings Inc is expected to release its next quarterly earnings report on 2025-May-13.
Sonnet BioTherapeutics Holdings Inc (NASDAQ:SONN)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.53% of Sonnet BioTherapeutics Holdings Inc shares while 5.24% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 5.32%.
